表紙
市場調査レポート

世界のパーキンソン病治療薬市場

Global Parkinson's Disease Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 278974
出版日 ページ情報 英文 97 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
世界のパーキンソン病治療薬市場 Global Parkinson's Disease Market 2014-2018
出版日: 2014年07月23日 ページ情報: 英文 97 Pages
概要

世界のパーキンソン病治療薬市場は、2013年〜2018年のCAGRで、3.32%の成長が見込まれています。

当レポートでは、世界のパーキンソン病治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 市場区分:作用機序別

  • 抗コリン薬
  • βアドレナリン遮断薬
  • COMT阻害薬
  • ドパミンアゴニスト
  • ドパミン補充薬
  • MAO-B阻害薬
  • その他

第8章 地域区分

第9章 購買基準

第10章 市場成長促進要因

第11章 促進要因とその影響

第12章 市場課題

第13章 促進要因と課題の影響

第14章 市場動向

第15章 動向とその影響

第16章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析

第17章 後期開発品候補

  • 後期開発品候補の主要情報
  • 後期開発品候補の開発中止

第18章 その他の有力ベンダー

第19章 主要ベンダー分析

  • 事業概要、事業戦略、SWOT分析など
    • Boehringer Ingelheim
    • GlaxoSmithKline
    • Novartis
    • Teva

第20章 関連レポート

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR3862

About Parkinson's Disease

Parkinson's disease is a progressive neurodegenerative disorder characterized by damage of dopaminergic neurons located in various parts of brain including the substantia nigra. This lowers the concentration of dopamine in the striatum. A decrease in dopamine levels by 80 percent leads to the development of symptoms associated with Parkinson's disease such as tremor, bradykinesia, and muscular rigidity. It is usually diagnosed in the population aged 60 and over; however, earlier incidences have been reported. Based on the severity, it can be categorized into early stage, mid stage and late (or advanced) stage. Currently, the approved therapies provide only symptomatic relief. Levodopa is the standard drug for the treatment of Parkinson's disease; however, it is associated with the incidence of dyskinesias. Alternative surgical procedures such as bilateral globus pallidus interna stimulation and bilateral subthalamic nucleus stimulation can be used in Parkinson's disease patients under certain circumstances.

TechNavio's analysts forecast the Global Parkinson's Disease market will grow at a CAGR of 3.32 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Parkinson's Disease market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to provide symptomatic relief in Parkinson's disease.

The report also presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the Global Parkinson's Disease market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Parkinson's Disease Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Parkinson's Disease market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.

Other Prominent Vendors

  • Abbvie Inc.
  • Akorn Inc.
  • Astellas Pharma Inc.
  • Desitin Arzneimittel GmbH
  • Endo International plc
  • F. Hoffmann-La Roche Ltd.
  • H. Lundbeck A/S
  • Kyowa Hakko Kirin
  • Merck & Co. Inc.
  • Orion Corp.
  • STADA Arzneimittel AG
  • UCB Inc.
  • US WorldMeds LLC
  • Valeant Pharmaceuticals International Inc.

Key Market Driver

  • Increase in Patient Population

For a full, detailed list, view our report.

Key Market Challenge

  • Generic Erosion

For a full, detailed list, view our report.

Key Market Trend

  • Reformulation of Marketed Drugs

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Market Segmentation by MOA

  • 07.1.1. Anticholinergics
  • 07.1.2. Beta-Adrenergic Antagonists
  • 07.1.3. COMT Inhibitors
  • 07.1.4. Dopamine Agonists
  • 07.1.5. Dopamine Replenishers
  • 07.1.6. MAOB Inhibitors
  • 07.1.7. Others

08. Geographical Segmentation

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape

  • 16.1. Competitive Scenario
    • 16.1.1. Key News
    • 16.1.2. Mergers and Acquisitions
  • 16.2. Market Share Analysis 2013
    • 16.2.1. Novartis
    • 16.2.2. Boehringer
    • 16.2.3. Teva
    • 16.2.4. GlaxoSmithKline

17. Key Late-Stage Pipeline Candidates

  • 17.1. Key Information for Late-Stage Pipeline Candidates
    • 17.1.1. ABT-SLV187
    • 17.1.2. BIA 9-1067
    • 17.1.3. IPX066
    • 17.1.4. KW-6002
    • 17.1.5. NW 1015
    • 17.1.6. OS-320
    • 17.1.7. P2B 001
  • 17.2. Key Late-Stage Discontinued Drug Candidates

18. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Boehringer Ingelheim
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Segmentation
    • 19.1.4. Business Strategy
    • 19.1.5. Revenue Segmentation by Business /Products
    • 19.1.6. Sales by Geographical Segmentation
    • 19.1.7. Key Information
    • 19.1.8. SWOT Analysis
    • 19.1.9. Strengths
    • 19.1.10. Weaknesses
    • 19.1.11. Opportunities
    • 19.1.12. Threats
  • 19.2. GlaxoSmithKline
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation
    • 19.2.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 19.2.5. Sales by Geography
    • 19.2.6. Pipeline Products
    • 19.2.7. Business Strategy
    • 19.2.8. Key Information
    • 19.2.9. SWOT Analysis
    • 19.2.10. Strengths
    • 19.2.11. Weaknesses
    • 19.2.12. Opportunities
    • 19.2.13. Threats
  • 19.3. Novartis
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation by Revenue 2013
    • 19.3.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 19.3.5. Sales by Geography
    • 19.3.6. Business Strategy
    • 19.3.7. Key Developments
    • 19.3.8. SWOT Analysis
    • 19.3.9. Strengths
    • 19.3.10. Weaknesses
    • 19.3.11. Opportunities
    • 19.3.12. Threats
  • 19.4. Teva
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation
    • 19.4.4. Business Segmentation by Revenue 2013
    • 19.4.5. Business Segmentation by Revenue 2012KKKKK and 2013
    • 19.4.6. Sales by Geography
    • 19.4.7. Business Strategy
    • 19.4.8. Key Developments
    • 19.4.9. SWOT Analysis
    • 19.4.10. Strengths
    • 19.4.11. Weakness
    • 19.4.12. Opportunities
    • 19.4.13. Threats

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Parkinson's Disease Market 2013-2018 (US$ billion)
  • Exhibit 3: Global Parkinson's Disease Market Segmentation by MOA
  • Exhibit 4: Anticholinergics Approved for the Treatment of Parkinson's Disease
  • Exhibit 5: Beta-Adrenergic Antagonists Approved for the Treatment of Parkinson's Disease
  • Exhibit 6: COMT Inhibitors Approved for the Treatment of Parkinson's Disease
  • Exhibit 7: Dopamine Agonists Approved for the Treatment of Parkinson's Disease
  • Exhibit 8: Dopamine Replenishers Approved for the Treatment of Parkinson's Disease
  • Exhibit 9: MAOB Inhibitors Approved for the Treatment of Parkinson's Disease
  • Exhibit 10: Some Other Drugs Approved for the Treatment of Parkinson's Disease
  • Exhibit 11: Global Parkinson's Disease Market by Geographical Segmentation 2013
  • Exhibit 12: Geography-wise Segmentation of Novartis' Comtan and Stalevo Sales 2013
  • Exhibit 13: Geography-wise Segmentation of Exelon's Sales in 2013
  • Exhibit 14: Geography-wise Revenue of Requip in 2013 (US$ million)
  • Exhibit 15: Business Segmentation of Boehringer Ingelheim Gmbh
  • Exhibit 16: Net Sales by Business of Boehringer Ingelheim GmbH
  • Exhibit 17: Revenue Segmentation by Business /Products (2013)
  • Exhibit 18: Sales by Geographical Segmentation (2013)
  • Exhibit 19: GlaxoSmithKline Plc: Business Segmentation 2013
  • Exhibit 20: GlaxoSmithKline Plc: Business Segmentation by Revenue 2012 and 2013 (in US$ billion)
  • Exhibit 21: GlaxoSmithKline Plc: Sales by Geography 2013
  • Exhibit 22: GlaxoSmithKline plc: Pipeline Products 2013
  • Exhibit 23: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 24: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 25: Novartis AG: Sales by Geography 2013
  • Exhibit 26: Teva Pharmaceutical Industries Ltd.: Business Segmentation
  • Exhibit 27: Teva Pharmaceutical Industries Ltd.: Business Segmentation by Revenue 2013
  • Exhibit 28: Teva Pharmaceutical Industries Ltd.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 29: Teva Pharmaceutical Industries Ltd.: Sales by Geography 2013
Back to Top